scholarly journals Changes in the level of interleukin-4 and interleukin-6 in response to angioprotective therapy in children with severe birth asphyxia

2020 ◽  
Vol 54 (1) ◽  
pp. 18-22
Author(s):  
Sergej Ovčarenko ◽  
Viktorija Danilova ◽  
Violeta Kalnicka
Keyword(s):  
Inflammatory Response ◽  
Interleukin 6 ◽  
Aerobic Glycolysis ◽  
Birth Asphyxia ◽  
Systemic Inflammatory Response ◽  
Wilcoxon Test ◽  
Interleukin 4 ◽  
Sign Test ◽  
Oxygen Utilization ◽  
Paired Samples

Objective. The development of clinical and laboratory criteria for diagnosis of systemic inflammatory response significantly expanded the use of this concept in clinical practice. The correlation between the levels of antiinflammatory and pro-inflammatory cytokines is an important aspect in regulation of systemic inflammatory response. Treatment of systemic inflammatory response includes three main links: effect on the levels of endotoxin, cytokines and the state of endothelium. Currently there is no unified approach to the solution of this problem, which determines the relevance of the topic. The aim of the research was to study the efficacy of the deproteinized hemodialysate from the newborn calf blood in systemic inflammatory response in newborns with severe asphyxia at birth. Methods. The study involved examination of 16 newborns with severe asphyxia at birth, who received a drug as part of standard therapy from the first day of the disease at a dose of 0.5 ml/kg. The study implied a follow-up assessment of interleukin-4 and interleukin-6 levels. Sign test and Wilcoxon test were used for paired samples; Kolmogorov-Smirnov and Mann-Whitney tests were used for non-paired samples. To investigate the influence of the independent variable on the dependent variable we used Kruskal-Wallis and median tests as nonparametric analogs of the variance analysis. Results. Deproteinized hemodialysate derived from the newborn calf blood is a vasoprotector and is a combination of a number of physiologically active ingredients. They stimulate oxygen utilization by tissues in hypoxic conditions, enhancing glucose transport through biological membranes, intensifying intracellular adenosine triphosphate synthesis, and increasing the proportion of aerobic glycolysis. Conclusion. Administration of deproteinized hemodialysate from the newborn calf blood in the treatment of systemic inflammatory response in newborns with severe asphyxia at birth exerts influence on biochemical pattern of systemic inflammatory response by reducing inflammation and reducing synthesis of cytokines.

scholarly journals Procalcitonin and Interleukin-6 for predicting culturenegative and culture positive bacterial sepsis in critically ill patients with systemic inflammatory response syndrome

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Mohd Basri Mat Nor ◽  
Azrina Md Ralib
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Interleukin 6 ◽  
Systemic Inflammatory Response ◽  
Bacterial Sepsis ◽  
Saps Ii Score ◽  
Culture Positive ◽  
Culture Negative

Introduction: Differentiation between culture-negative bacterial sepsis (BS), culturepositive BS and non-infectious systemic inflammatory response syndrome (SIRS) among critically ill patients remains a diagnostic challenge to the intensive care unit (ICU) physicians. This study aimed to evaluate the role of procalcitonin (PCT) and interleukin-6 (IL-6) in predicting non-infectious SIRS, culture-negative BS and culture-positive BS in the ICU. Methods: This prospective observational study was conducted in a tertiary ICU in Pahang. The patients were divided into sepsis and non-infectious SIRS based on clinical assessment with or without positive cultures. Patients with positive cultures were further divided into bacteraemia and positive other culture. The PCT and IL-6 were measured daily over the first 3 days. Results: Two hundred and thirty nine consecutive patients diagnosed with SIRS were recruited, of whom 164 (69%) had sepsis. Among sepsis patients, there were 62 (37.8%) culture positive and 102 (62.2%) culture negative. Of these, 27 (16.5%) develop bacteraemia. The most common site of infection was respiratory (34.4%). Post-LSD analyses showed significant difference in the PCT between culture negative sepsis and SIRS (p=0.01); and positive other culture and SIRS (p=0.04).  On the other hand IL-6 cannot differentiate between SIRS and negative culture sepsis (p=0.06). Both PCT and IL-6 predicted bacteraemia with an AUC of 0.70 (0.57 to 0.82) and 0.68 (0.53 to 0.70). IL-6 is independently associated with bacteraemia and other culture after adjusting for age, sex, hypertension, SAPS II score and day 1 PCT. Conclusions: Procalcitonin but not Interleukin-6 is able to differentiate SIRS from culture-negative BS. However, IL-6 is independently associated with bacteraemia and other culture.

Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 267-267
Author(s):  
Inna Chen ◽  
Christian Dehlendorff ◽  
Benny Vittrup Jensen ◽  
Per Pfeiffer ◽  
Jon K. Bjerregaard ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Inflammatory Response ◽  
Interleukin 6 ◽  
Prognostic Value ◽  
Univariate Analysis ◽  
White Blood Cells ◽  
Multivariable Analysis ◽  
Laboratory Data ◽  
Cox Proportional Hazards ◽  
Systemic Inflammatory Response

267 Background: Interleukin-6 (IL-6) and YKL-40 (CHI3L1) are produced by pancreatic cancer (PC) cells and macrophages and activate inflammation. The aim of this prospective-retrospective biomarker study was to determine the prognostic value of serum IL-6 and YKL-40 and systemic inflammatory response in patients with PC receiving palliative chemotherapy. Methods: 625 patients with PC (M/F: 283/342; age <70 vs. ≥70: 395/230; ECOG PS of 0/1/2/3: 214/315/92/4; stage 3 vs. 4: 129/496; treated with gemcitabine n=437, FOLFIRINOX n=117, gemcitabine and nab-Paclitaxel n=54 or other n=17) were included in the BIOPAC biomarker study from 5 hospitals in Denmark. Pretreatment serum values of IL-6 (R&D Systems), YKL-40 (Quidel), and CA 19-9 (Siemens) were determined. Patients were grouped as low vs. high, dichotomized using cut-off for IL-6 > 4.92 pg/ml, for CA19-9 > 2183 U/ml and for YKL-40 > 95% age-corrected percentile. The main outcome was overall survival (OS) and hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were computed using Cox proportional hazards regression. Results: 598 (95.7%) patients died during follow-up. In univariate analysis elevated IL-6 (HR 1.93, 95% CI 1.63-2.28) and elevated YKL-40 (HR 1.74, 95% CI 1.47-2.05) were associated with short OS. Similar results were found if IL-6 and YKL-40 were included as continuous log2-transformed variables. Multivariable analysis showed that elevated IL-6 (HR 1.61, 95% CI 1.33-1.94), elevated YKL-40 (HR 1.36, 95% CI 1.13-1.64), elevated CA19-9 (HR 1.30, 95% CI 1.09-1.56), higher PS (1 vs. 0; HR 1.46, 95% CI 1.21-1.77 and PS 2 vs. 0; HR 2.73, 95% CI 2.08-3.58) and stage 4 vs. 3 (HR 1.79, 95% CI 1.44-2.24) were independently associated with a poor OS. In a subgroup of 386 patients with available laboratory data, higher C-reactive protein (HR 1.20, 95% CI 1.13-1.26), white blood cells (HR 1.41, 1.17-1.71) and absolute neutrophils count (HR 1.35, 95% CI 1.15-1.59) log2-transformed and adjusted for age, sex, PS, CA 19-9 and stage were associated with short OS. Conclusions: Serum IL-6, YKL-40 and CA19-9 along with CRP, WBC and ANC are independent prognostic biomarkers in patients with unresectable PC.

Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome

1999 ◽  
Vol 27 (7) ◽  
pp. 1262-1264 ◽  
Author(s):  
Takumi Taniguchi ◽  
Yuichi Koido ◽  
Jyunichi Aiboshi ◽  
Teruyo Yamashita ◽  
Shinichiro Suzaki ◽  
...  
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Interleukin 6 ◽  
Interleukin 10 ◽  
Systemic Inflammatory Response ◽  
Poor Outcome

Interleukin 6 and interleukin 8 play important roles in systemic inflammatory response syndrome of meconium peritonitis

Surgery Today ◽  
2011 ◽  
Vol 42 (5) ◽  
pp. 431-434 ◽  
Author(s):  
Yutaka Kanamori ◽  
Kan Terawaki ◽  
Hajime Takayasu ◽  
Masahiko Sugiyama ◽  
Makoto Komura ◽  
...  
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Interleukin 6 ◽  
Systemic Inflammatory Response ◽  
Interleukin 8 ◽  
Meconium Peritonitis

scholarly journals Enteric bacterial loads are associated with interleukin-6 levels in systemic inflammatory response syndrome patients

2016 ◽  
Vol 49 (6) ◽  
pp. 208-216 ◽  
Author(s):  
Tzyy-Bin Tsay ◽  
Ming-Chieh Yang ◽  
Jen-Tang Sun ◽  
Pei-Hsuan Chen ◽  
Ying-Sheng Lin ◽  
...  
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Interleukin 6 ◽  
Systemic Inflammatory Response

scholarly journals Anti-inflammatory response of IL-4, IL-10 and TGF-β in patients with systemic inflammatory response syndrome

2000 ◽  
Vol 9 (3-4) ◽  
pp. 193-195 ◽  
Author(s):  
Donato Torre ◽  
Roberto Tambini ◽  
Silvana Aristodemo ◽  
Giovanna Gavazzeni ◽  
Antonio Goglio ◽  
...  
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Systemic Inflammatory Response ◽  
Interleukin 4 ◽  
Significant Difference ◽  
Anti Inflammatory

The systemic inflammatory response syndrome (SIRS) is an inflammatory process seen in association with a large number of clinical infective and noninfective conditions.The aim of this study was to investigate the role of anti-inflammatory cytokines such as interleukin–4 (IL–4), interleukin–10 (IL–10), and transforming growth factor-beta (TGF-beta). Serum levels of IL–4, IL–10 and TGF-β were determined in 45 patients with SIRS: 38 patients had SIRS of infectious origin, whereas seven patients had non-infectious SIRS. Twenty healthy subjects were used as controls.Serum levels of IL–4, IL–10 and TGFg were determined by an immunoenzyme assay. A significant increase of IL–4 was observed in these patients at the time of diagnosis and 5 days later. In contrast, serum levels of IL–10 were not increased at the time of diagnosis, but a slight decrease was noted after 5 days. Serum levels of TGF-β were not increased at time of diagnosis, and a slight increase was observed after 5 days. Serum levels of IL–4 were significantly higher in patients with infectious SIRS at the time of diagnosis, whereas no significant difference between infectious and non-infectious SIRS was noted for serum levels of IL–10 and TGF-β at the time of diagnosis and 5 days later.During SIRS, serum levels of IL–4 were significantly increased with a significant correlation between IL–4 and mortality, and only levels of IL–4 were significantly increased in the SIRS caused by infectious stimuli.

Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency

1999 ◽  
Vol 96 (3) ◽  
pp. 287-295 ◽  
Author(s):  
Annika TAKALA ◽  
Irma JOUSELA ◽  
Klaus T. OLKKOLA ◽  
Sten-Erik JANSSON ◽  
Marjatta LEIRISALO-REPO ◽  
...  
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Systemic Inflammation ◽  
Interleukin 6 ◽  
Systemic Inflammatory Response ◽  
Composite Score ◽  
C Reactive Protein ◽  
Cd11b Expression ◽  
Reactive Protein ◽  
Markers Of Inflammation

Criteria of the systemic inflammatory response syndrome (SIRS) are known to include patients without systemic inflammation. Our aim was to explore additional markers of inflammation that would distinguish SIRS patients with systemic inflammation from patients without inflammation. The study included 100 acutely ill patients with SIRS. Peripheral blood neutrophil and monocyte CD11b expression, serum interleukin-6, interleukin-1β, tumour necrosis factor-α and C-reactive protein were determined, and severity of inflammation was evaluated by systemic inflammation composite score based on CD11b expression, C-reactive protein and cytokine levels. Levels of CD11b expression, C-reactive protein and interleukin-6 were higher in sepsis patients than in SIRS patients who met two criteria (SIRS2 group) or three criteria of SIRS (SIRS3 group). The systemic inflammation composite score of SIRS2 patients (median 1.5; range 0–8, n = 56) was lower than that of SIRS3 patients (3.5; range 0–9, n = 14, P = 0.013) and that of sepsis patients (5.0; range 3–10, n = 19, P< 0.001). The systemic inflammation composite score was 0 in 13/94 patients. In 81 patients in whom systemic inflammation composite scores exceeded 1, interleukin-6 was increased in 64 (79.0%), C-reactive protein in 59 (72.8%) and CD11b in 50 (61.7%). None of these markers, when used alone, identified all patients but at least one marker was positive in each patient. Quantifying phagocyte CD11b expression and serum interleukin-6 and C-reactive protein concurrently provides a means to discriminate SIRS patients with systemic inflammation from patients without systemic inflammation.

scholarly journals The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

2020 ◽  
Vol 8 (1) ◽  
pp. e000930 ◽  
Author(s):  
Fernanda I Arnaldez ◽  
Steven J O'Day ◽  
Charles G Drake ◽  
Bernard A Fox ◽  
Bingqing Fu ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Interleukin 6 ◽  
Severe Disease ◽  
Systemic Inflammatory Response ◽  
Interleukin 17 ◽  
Extensive Experience ◽  
Necrosis Factor Alpha ◽  
The Usa ◽  
Immunotherapy Of Cancer ◽  
Novel Coronavirus

The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often accompanied by a pathological immune reaction, sometimes referred to as ‘cytokine storm’. One hallmark feature of the profound inflammatory state seen in patients with COVID-19 who succumb to pneumonia and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved outcomes for critically ill patients with COVID-19 with the administration of cytokine-modulatory therapies, especially anti-IL-6 agents. Although ongoing trials are investigating anti-IL-6 therapies, access to these therapies is a concern, especially as the numbers of cases worldwide continue to climb. An immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in patients with COVID-19. Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19.

Sign in / Sign up

Export Citation Format

Share Document